aTyr Pharma Reports the First Patient Dosing in the P-III (EFZO-FIT) Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Shots:
- The first patient has been dosed in the P-III (EFZO-FIT) study to evaluate the efficacy and safety of the efzofitimod (3.0/5.0mg/kg) vs PBO in 264 patients with pulmonary sarcoidosis at multiple centers in North America, EU & Japan
- The 1EPs of the study will evaluate the steroid-sparing effect while the 2EPs include measures of lung function and sarcoidosis symptoms
- The (EFZO-FIT) study builds on the results from P-Ib/IIa study which showed a dose-dependent improvement across steroid reduction, lung function & symptom control EPs. Efzofitimod is an immunomodulator that selectively modifies NRP2 to suppress innate and adaptive immune responses in uncontrolled inflammatory disease conditions
Ref: Globenewswire | Image: aTyr Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
